ACLU sues FDA for records on abortion pill review
- The ACLU has sued the FDA for not complying with the Freedom of Information Act regarding its review of the abortion pill mifepristone, calling for transparency in its proceedings.
- The lawsuit demands compliance with the Freedom of Information Act following previous requests that the FDA did not address.
- Mifepristone, the most common medicine for abortions, accounted for 1 in 4 abortions in 2023 and is deemed safe compared to other medications.
- Rachel Reeves emphasized the need for transparency, stating that the current administration fails to provide available information about medication abortion.
15 Articles
15 Articles
FDA’s abortion-pill safety review under growing scrutiny
U.S. Health and Human Services Secretary Robert F. Kennedy Jr., shown here in September, cited a white paper funded and self-published without peer review by anti-abortion groups as grounds for federal scrutiny of a key abortion medication’s safety. (Photo by Andrew Harnik/Getty Images)The U.S. Food and Drug Administration is facing increasing pressure from abortion opponents and advocates over how it regulates a drug that has become central to …
FDA Hit With 2nd Lawsuit Over Needless Abortion Pill Investigation
Under our brain-wormed HHS secretary RFK Jr. and FDA Commissioner Marty Makary (who has called the U.S. “underbabied”), the FDA has been incredibly dodgy in its proceedings and its reliance on junk science, including using a far-right “study” to baselessly launch an investigation into the abortion bill mifepristone—the second of two pills taken during a medication abortion. On Thursday, the ACLU sued the FDA for revealing close to nothing about …
ACLU sues FDA for records on abortion pill review
The American Civil Liberties Union, ACLU, filed a lawsuit Thursday to compel the Food and Drug Administration, FDA, to disclose records related to the agency’s review of its regulations on mifepristone, a medication used in most U.S. abortions. The lawsuit seeks to enforce the ACLU’s Freedom of Information Act, FOIA, request, filed in August, which seeks information about the scope of the review along with any communications between the FDA and …
Coverage Details
Bias Distribution
- 92% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium





